{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:11:24Z","timestamp":1795090284695,"version":"4.10.2"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["101034339"],"award-info":[{"award-number":["101034339"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NIHR Health Protection Research Units","award":["NIHR200908 and NIHR200929"],"award-info":[{"award-number":["NIHR200908 and NIHR200929"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-03970-x","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T17:54:48Z","timestamp":1742838888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: a multi-country analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lander","family":"Willem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Klint","family":"Johannesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Urchuegu\u00eda-Fornes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Lehtonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Osei-Yeboah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heini","family":"Salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Orrico-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"D\u00edez-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for PROMISE investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Openshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Nohynek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Paget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Molero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"D\u00edez-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Janimak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Begier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hendri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Bilcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"issue":"1","key":"3970_CR1","doi-asserted-by":"publisher","first-page":"e13031","DOI":"10.1111\/irv.13031","volume":"17","author":"M Savic","year":"2023","unstructured":"Savic M, Penders Y, Shi T, Branche A, Pircon JY. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2023;17(1):e13031.","journal-title":"Influenza Other Respir Viruses"},{"key":"3970_CR2","doi-asserted-by":"publisher","unstructured":"Li Y, Wang X, Broberg EK, Campbell H, Nair H. European RSV Surveillance Network. Seasonality of respiratory syncytial virus and its association with meteorological factors in 13 European countries, week 40 2010 to week 39 2019. Euro Surveill. 2022;27(16):2100619. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.16.2100619.\u00a0","DOI":"10.2807\/1560-7917.ES.2022.27.16.2100619"},{"issue":"Suppl 1","key":"3970_CR3","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/infdis\/jiab040","volume":"226","author":"T Shi","year":"2022","unstructured":"Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H. Disease Burden Estimates of Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With Comorbidity: A Systematic Review and Meta-Analysis. J Infect Dis. 2022;226(Suppl 1):S17\u2013s21.","journal-title":"J Infect Dis"},{"issue":"24","key":"3970_CR4","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J, Duncan CJA, Ujiie M, Ramet M, et al. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023;389(24):2233\u201344.","journal-title":"N Engl J Med"},{"issue":"16","key":"3970_CR5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh EE, P\u00e9rez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023;388(16):1465\u201377.","journal-title":"N Engl J Med"},{"issue":"7","key":"3970_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023;388(7):595\u2013608.","journal-title":"N Engl J Med"},{"key":"3970_CR7","doi-asserted-by":"publisher","unstructured":"Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstr\u00f8m V, Olivier A, Van der Wielen M, Descamps D. AReSVi-006 Study Group. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024;78(6):1732\u201344. https:\/\/doi.org\/10.1093\/cid\/ciae010.\u00a0","DOI":"10.1093\/cid\/ciae010"},{"key":"3970_CR8","unstructured":"Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO\u00ae for RSV in Older Adults [https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-positive-top-line-data-full-season-two]"},{"key":"3970_CR9","unstructured":"ACIP Recommendations [https:\/\/www.cdc.gov\/vaccines\/acip\/recommendations.html]"},{"key":"3970_CR10","unstructured":"Respiratory syncytial virus (RSV) immunisation programme: JCVI advice, 7 June 2023 [https:\/\/www.gov.uk\/government\/publications\/rsv-immunisation-programme-jcvi-advice-7-june-2023\/respiratory-syncytial-virus-rsv-immunisation-programme-jcvi-advice-7-june-2023]"},{"issue":"3","key":"3970_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/cid\/ciad161","volume":"77","author":"T Van Effelterre","year":"2023","unstructured":"Van Effelterre T, Hens N, White LJ, Gravenstein S, Bastian AR, Buyukkaramikli N, Cheng CY, Hartnett J, Krishnarajah G, Weber K, et al. Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model. Clin Infect Dis. 2023;77(3):480\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3970_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2165\/00019053-199712060-00003","volume":"12","author":"A Alban","year":"1997","unstructured":"Alban A, Gyldmark M, Pedersen AV, Sogaard J. The Danish approach to standards for economic evaluation methodologies. Pharmacoeconomics. 1997;12(6):627\u201336.","journal-title":"Pharmacoeconomics"},{"key":"3970_CR13","unstructured":"Preparing a Health Economic Evaluation to Be Attached to the Application for Reimbursement Status and Wholesale Price for a Medicinal Product. Application Instructions (December 2019) [https:\/\/tools.ispor.org\/PEguidelines\/source\/2011Pricing_Board_Guidance_HEevaluation_english.pdf]"},{"key":"3970_CR14","unstructured":"Hakkaart-van Roijen L, Peeters S, Kanters T. Kostenhandleiding voor economische evaluaties in de gezondheidszorg: Methodologie en Referentieprijzen (Herziene versie 2024). In. Edited by Institute for Medical Technology Assessment Erasmus Universiteit Rotterdam. Online; 2024. https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/publicatie\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg\/Verdiepingsmodule+Kostenhandleiding+%28versie+2024%29.pdf."},{"issue":"2","key":"3970_CR15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","volume":"24","author":"J Lopez Bastida","year":"2010","unstructured":"Lopez Bastida J, Oliva J, Antonanzas F, Garcia-Altes A, Gisbert R, Mar J, Puig-Junoy J. A proposed guideline for economic evaluation of health technologies. Gac Sanit. 2010;24(2):154\u201370.","journal-title":"Gac Sanit"},{"issue":"Suppl 1","key":"3970_CR16","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1093\/infdis\/jiac059","volume":"226","author":"RM Reeves","year":"2022","unstructured":"Reeves RM, van Wijhe M, Lehtonen T, Stona L, Teirlinck AC, Vazquez Fernandez L, Li Y, Osei-Yeboah R, Fischer TK, Heikkinen T, et al. A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis. J Infect Dis. 2022;226(Suppl 1):S110\u20136.","journal-title":"J Infect Dis"},{"key":"3970_CR17","doi-asserted-by":"publisher","unstructured":"Egeskov-Cavling AM, Johannesen CK, Lindegaard B, Fischer TK. PROMISE Investigators. Underreporting and Misclassification of Respiratory Syncytial Virus-Coded Hospitalization Among Adults in Denmark Between 2015-2016 and 2017-2018. J Infect Dis. 2024;229(Supplement_1):S78-83. https:\/\/doi.org\/10.1093\/infdis\/jiad415.\u00a0","DOI":"10.1093\/infdis\/jiad415"},{"issue":"2","key":"3970_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/irv.12937","volume":"16","author":"A Mira-Iglesias","year":"2022","unstructured":"Mira-Iglesias A, Demont C, Lopez-Labrador FX, Mengual-Chulia B, Garcia-Rubio J, Carballido-Fernandez M, Tortajada-Girbes M, Mollar-Maseres J, Schwarz-Chavarri G, Puig-Barbera J, et al. Role of age and birth month in infants hospitalized with RSV-confirmed disease in the Valencia Region. Spain Influenza Other Respir Viruses. 2022;16(2):328\u201339.","journal-title":"Spain. Influenza Other Respir Viruses"},{"key":"3970_CR19","doi-asserted-by":"publisher","unstructured":"Mira-Iglesias A, L\u00f3pez-Labrador FX, Guglieri-L\u00f3pez B, Tortajada-Girb\u00e9s M, Baselga-Moreno V, Cano L, Mollar-Maseres J, Carballido-Fern\u00e1ndez M, Schwarz-Chavarri G, D\u00edez-Domingo J, Puig-Barber\u00e0 J. Valencia Hospital Network for the Study of Influenza and Respiratory Viruses Disease. Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016\/17. Euro Surveill. 2018;23(8):17\u201300318. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.8.17-00318.\u00a0","DOI":"10.2807\/1560-7917.ES.2018.23.8.17-00318"},{"key":"3970_CR20","unstructured":"The European Commission: DECISIONS COMMISSION IMPLEMENTING DECISION (EU) 2018\/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions. Official Journal of the European Union. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32018D0945."},{"key":"3970_CR21","doi-asserted-by":"publisher","unstructured":"Johannesen CK, Gideonse D, Osei-Yeboah R, Lehtonen T, Jollivet O, Cohen RA, Urchuegu\u00eda-Fornes A, Herrero-Silvestre M, L\u00f3pez-Lacort M, Kramer R, Fischer TK, Heikkinen T, Nair H, Campbell H, van Boven M. PROMISE investigators. Estimation of respiratory syncytial virus-associated hospital admissions in five European countries: a modelling study. Lancet Reg Health Eur. 2025;51:101227. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101227.\u00a0","DOI":"10.1016\/j.lanepe.2025.101227"},{"key":"3970_CR22","doi-asserted-by":"publisher","unstructured":"Johannesen CK, van Wijhe M, Tong S, Fern\u00e1ndez LV, Heikkinen T, van Boven M, Wang X, B\u00f8\u00e5s H, Li Y, Campbell H, Paget J, Stona L, Teirlinck A, Lehtonen T, Nohynek H, Bangert M, Fischer TK. RESCEU Investigators. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis. J Infect Dis. 2022;226(Suppl 1):S29\u201337. https:\/\/doi.org\/10.1093\/infdis\/jiac150.","DOI":"10.1093\/infdis\/jiac150"},{"key":"3970_CR23","doi-asserted-by":"publisher","unstructured":"Urchuegu\u00eda-Fornes A, Osei-Yeboah R, Jollivet O, Johannesen CK, Lehtonen T, van Boven M, Gideonse D, Cohen RA, Orrico-S\u00e1nchez A, Kramer R, et al. RSV healthcare burden in adults before and since the emergence of the COVID-19 pandemic in 6 European countries. medRxiv. 2024.09.20.24314093. https:\/\/doi.org\/10.1101\/2024.09.20.24314093.","DOI":"10.1101\/2024.09.20.24314093"},{"issue":"4","key":"3970_CR24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s40121-023-00792-3","volume":"12","author":"Y Li","year":"2023","unstructured":"Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, Nair H. Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling Study. Infect Dis Ther. 2023;12(4):1137\u201349.","journal-title":"Infect Dis Ther"},{"key":"3970_CR25","doi-asserted-by":"publisher","unstructured":"McLaughlin JM, Khan F, Schmitt HJ, Agosti Y, Jodar L, Sim\u00f5es EAF, Swerdlow DL. Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis. J Infect Dis. 2022;225(6):1100\u201311. https:\/\/doi.org\/10.1093\/infdis\/jiaa752.\u00a0","DOI":"10.1093\/infdis\/jiaa752"},{"key":"3970_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12879-015-1218-z","volume":"15","author":"DM Fleming","year":"2015","unstructured":"Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, Logie J, Matias G, Taylor S. Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis. 2015;15:443.","journal-title":"BMC Infect Dis"},{"key":"3970_CR27","doi-asserted-by":"publisher","unstructured":"Korsten K, Adriaenssens N, Coenen S, Butler C, Ravanfar B, Rutter H, Allen J, Falsey A, Pir\u00e7on JY, Gruselle O, Pavot V, Vernhes C, Balla-Jhagjhoorsingh S, \u00d6ner D, Ispas G, Aerssens J, Shinde V, Verheij T, Bont L, Wildenbeest J. RESCEU investigators. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J. 2021;57(4):2002688. https:\/\/doi.org\/10.1183\/13993003.02688-2020.\u00a0","DOI":"10.1183\/13993003.02688-2020"},{"issue":"Suppl 1","key":"3970_CR28","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1093\/infdis\/jiac069","volume":"226","author":"Z Mao","year":"2022","unstructured":"Mao Z, Li X, Korsten K, Bont L, Butler C, Wildenbeest J, Coenen S, Hens N, Bilcke J, Beutels P. Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults. J Infect Dis. 2022;226(Suppl 1):S87\u2013s94.","journal-title":"J Infect Dis"},{"key":"3970_CR29","unstructured":"Hutton DW. Economic Analysis of RSV Vaccination in Older Adults. In: ACIP Presentation Slides: June 21-23, 2023 Meeting: 2023. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2023-02\/slides-02-23\/RSV-Adults-02-Hutton-508.pdf."},{"key":"3970_CR30","unstructured":"Ortega-Sanchez IR. Economics of Vaccinating U.S. Adults \u226560 years-old against Respiratory Syncytial Virus. In: ACIP Presentation Slides: June 21-23, 2023 Meeting: 2023. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2023-06-21-23.html."},{"key":"3970_CR31","doi-asserted-by":"publisher","unstructured":"Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC, Galvani AP. Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States. Clin Infect Dis. 2024;78(5):1328\u201335. https:\/\/doi.org\/10.1093\/cid\/ciad658.\u00a0","DOI":"10.1093\/cid\/ciad658"},{"key":"3970_CR32","doi-asserted-by":"publisher","unstructured":"Wang Y, Fekadu G, You JHS. Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong. Vaccines (Basel). 2023;11(10):1605. https:\/\/doi.org\/10.3390\/vaccines11101605.\u00a0","DOI":"10.3390\/vaccines11101605"},{"issue":"17","key":"3970_CR33","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1016\/j.vaccine.2011.09.079","volume":"30","author":"J Bilcke","year":"2012","unstructured":"Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine. 2012;30(17):2795\u2013800.","journal-title":"Vaccine"},{"issue":"3","key":"3970_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1128\/CVI.00604-15","volume":"23","author":"AJ Dunning","year":"2016","unstructured":"Dunning AJ, DiazGranados CA, Voloshen T, Hu B, Landolfi VA, Talbot HK. Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial. Clin Vaccine Immunol. 2016;23(3):228\u201335.","journal-title":"Clin Vaccine Immunol"},{"key":"3970_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","volume":"40","author":"A Ciabattini","year":"2018","unstructured":"Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: The challenge of immune changes with aging. Semin Immunol. 2018;40:83\u201394.","journal-title":"Semin Immunol"},{"key":"3970_CR36","unstructured":"GSK: Arexvy product leaflet in the European Scientific Working Group on Influenza (ESWI) conference, Valencia. 2023."},{"key":"3970_CR37","unstructured":"Heins M, Knottnerus B, Matser A, Hooiveld M. Vaccine Coverage Dutch National Influenza Prevention Program 2022: brief monitor. In.: Netherlands Institute for Health Services Research (NIVEL); 2023. https:\/\/www.nivel.nl\/nl\/publicatie\/vaccine-coverage-dutch-national-influenza-prevention-program-2022-brief-monitor."},{"key":"3970_CR38","unstructured":"Influenza season 2021\/2022 [https:\/\/en.ssi.dk\/surveillance-and-preparedness\/surveillance-in-denmark\/annual-reports-on-disease-incidence\/influenza-season-2021-2022]"},{"key":"3970_CR39","unstructured":"Marciano G\u00f3mez anima a la vacunaci\u00f3n como medida m\u00e1s eficaz para protegerse frente a los virus respiratorios [https:\/\/comunica.gva.es\/es\/detalle?id=377968997&site=373422400]"},{"key":"3970_CR40","unstructured":"Declareren vaccinaties [https:\/\/www.snpg.nl\/article\/griep-ha-afronden\/declareren-griepvaccinaties\/vergoeding\/#:~:text=U%20ontvangt%20een%20vergoeding%20voor,14%2C01%20per%20toegediend%20vaccin.]"},{"key":"3970_CR41","unstructured":"M\u00e4klin S, Kokko P. Terveyden- ja sosiaalihuollon yksikk\u00f6kustannukset Suomessa vuonna 2017. 2020. https:\/\/www.julkari.fi\/handle\/10024\/142882."},{"key":"3970_CR42","doi-asserted-by":"publisher","unstructured":"Jacob J, Biering-S\u00f8rensen T, Holger Ehlers L, Edwards CH, Mohn KG, Nilsson A, Hjelmgren J, Ma W, Sharma Y, Ciglia E, Mould-Quevedo J. Cost-Effectiveness of Vaccination of Older Adults with an MF59\u00ae-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden. Vaccines (Basel). 2023;11(4):753. https:\/\/doi.org\/10.3390\/vaccines11040753.\u00a0","DOI":"10.3390\/vaccines11040753"},{"issue":"10","key":"3970_CR43","doi-asserted-by":"publisher","first-page":"e0270835","DOI":"10.1371\/journal.pone.0270835","volume":"17","author":"H Nieminen","year":"2022","unstructured":"Nieminen H, Hakulinen T, Puumalainen T, Siren P, Palmu AA. Time and labour costs of preventive health care, including vaccinations, in Finnish child health clinics. PLoS One. 2022;17(10):e0270835.","journal-title":"PLoS One"},{"issue":"36","key":"3970_CR44","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1016\/j.vaccine.2021.07.048","volume":"39","author":"E Redondo","year":"2021","unstructured":"Redondo E, Drago G, Lopez-Belmonte JL, Guillen JM, Bricout H, Alvarez FP, Callejo D. Gil de Miguel A: Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine. Vaccine. 2021;39(36):5138\u201345.","journal-title":"Vaccine"},{"key":"3970_CR45","unstructured":"Mean and median income by age and sex - EU-SILC and ECHP surveys [https:\/\/ec.europa.eu\/eurostat\/databrowser\/product\/page\/ILC_DI03__custom_3025743]"},{"key":"3970_CR46","unstructured":"Employment rates by sex, age and citizenship [https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/lfsa_ergan\/default\/table?lang=en]"},{"key":"3970_CR47","doi-asserted-by":"crossref","unstructured":"Zeevat F, Luttjeboer J, Paulissen JHJ, van der Schans J, Beutels P, Boersma C, Postma MJ, Investigators R: Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom. J Infect Dis 2022, 226(Supplement_1):S102-S109.","DOI":"10.1093\/infdis\/jiab118"},{"key":"3970_CR48","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4"},{"key":"3970_CR49","unstructured":"HICP - annual data (average index and rate of change) [https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/prc_hicp_aind\/default\/table?lang=en&category=prc.prc_hicp]"},{"key":"3970_CR50","unstructured":"ECU\/EUR exchange rates versus national currencies [https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/tec00033\/default\/table?lang=en]"},{"issue":"2","key":"3970_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen MF, Szende A, Cabases J, Ramos-Goni JM, Vilagut G, Konig HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205\u201316.","journal-title":"Eur J Health Econ"},{"key":"3970_CR52","unstructured":"Koskinen S, Lundqvist A, Ristiluoma N. Health, functional capacity and welfare in Finland in 2011. In. Helsinki, Finland: National Institute for Health and Welfare (THL); 2012. https:\/\/www.julkari.fi\/bitstream\/handle\/10024\/90832\/Rap068_2012_netti.pdf?sequence=1&isAllowed=y."},{"key":"3970_CR53","doi-asserted-by":"publisher","unstructured":"Mao Z, Li X, Dacosta-Urbieta A, Billard MN, Wildenbeest J, Korsten K, Martin\u00f3n-Torres F, Heikkinen T, Cunningham S, Snape MD, Robinson H, Pollard AJ, Postma M, Dervaux B, Hens N, Bont L, Bilcke J, Beutels P; for RESCEU investigators. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe. Vaccine. 2023;41(16):2707\u201315. https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.024.\u00a0","DOI":"10.1016\/j.vaccine.2023.03.024"},{"issue":"24","key":"3970_CR54","doi-asserted-by":"publisher","first-page":"126294","DOI":"10.1016\/j.vaccine.2024.126294","volume":"42","author":"DW Hutton","year":"2024","unstructured":"Hutton DW, Prosser LA, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ, Havers FP, Prill MM, Whitaker M, Roper LE, et al. Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus. Vaccine. 2024;42(24):126294.","journal-title":"Vaccine"},{"issue":"4","key":"3970_CR55","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/0272989X211045070","volume":"42","author":"J Bilcke","year":"2022","unstructured":"Bilcke J, Beutels P. Generating, Presenting, and Interpreting Cost-Effectiveness Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better Practice. Med Decis Making. 2022;42(4):421\u201335.","journal-title":"Med Decis Making"},{"key":"3970_CR56","doi-asserted-by":"crossref","unstructured":"Briggs AC, K. Sculpher, M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"issue":"5","key":"3970_CR57","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jval.2019.02.008","volume":"22","author":"F Alarid-Escudero","year":"2019","unstructured":"Alarid-Escudero F, Enns EA, Kuntz KM, Michaud TL, Jalal H. \u201cTime Traveling Is Just Too Dangerous\u201d but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. Value Health. 2019;22(5):611\u20138.","journal-title":"Value Health"},{"issue":"5","key":"3970_CR58","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/0272989X20937253","volume":"40","author":"Z Pieters","year":"2020","unstructured":"Pieters Z, Strong M, Pitzer VE, Beutels P, Bilcke J. A Computationally Efficient Method for Probabilistic Parameter Threshold Analysis for Health Economic Evaluations. Med Decis Making. 2020;40(5):669\u201379.","journal-title":"Med Decis Making"},{"key":"3970_CR59","doi-asserted-by":"crossref","unstructured":"Johannesen CK, Gideonse D, Osei-Yeboah R, Lehtonen T, Jollivet O, Cohen RA, Urchuegu\u00eda-Fornes A, Herrero-Silvestre M, L\u00f3pez-Lacort M, Kramer R et al: Estimation of respiratory syncytial virus-associated hospital admissions in five European countries: a modelling study. The Lancet Regional Health \u2013 Europe 2025, 51:101227.","DOI":"10.1016\/j.lanepe.2025.101227"},{"key":"3970_CR60","doi-asserted-by":"publisher","unstructured":"Begier E, Aliabadi N, Ramirez J, McGeer A, Liu Q, Carrico R, Mubareka S, Uppal S, Furmanek S, Zhong Z, et al. Detection of RSV using nasopharyngeal swabs alone underestimates RSV-related hospitalization incidence in adults: the Multispecimen study\u2019s Final Analysis. medRxiv (preprint). 2025. https:\/\/doi.org\/10.1101\/2025.01.14.25320406.","DOI":"10.1101\/2025.01.14.25320406"},{"issue":"6","key":"3970_CR61","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/irv.12665","volume":"14","author":"W Cai","year":"2020","unstructured":"Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, Buda S. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):630\u20137.","journal-title":"Influenza Other Respir Viruses"},{"key":"3970_CR62","doi-asserted-by":"publisher","unstructured":"S\u00e1ez-L\u00f3pez E, Pechirra P, Costa I, Crist\u00f3v\u00e3o P, Conde P, Machado A, Rodrigues AP, Guiomar R. Performance of surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza surveillance system, Portugal, 2010 to 2018. Euro Surveill. 2019;24(45):1900140. https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.45.1900140.","DOI":"10.2807\/1560-7917.ES.2019.24.45.1900140"},{"issue":"6","key":"3970_CR63","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/irv.12688","volume":"14","author":"S Hirve","year":"2020","unstructured":"Hirve S, Crawford N, Palekar R, Zhang W. Group WRs: Clinical characteristics, predictors, and performance of case definition-Interim results from the WHO global respiratory syncytial virus surveillance pilot. Influenza Other Respir Viruses. 2020;14(6):647\u201357.","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"3970_CR64","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12916-020-01802-8","volume":"18","author":"D Hodgson","year":"2020","unstructured":"Hodgson D, Pebody R, Panovska-Griffiths J, Baguelin M, Atkins KE. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis. BMC Med. 2020;18(1):348.","journal-title":"BMC Med"},{"issue":"5","key":"3970_CR65","doi-asserted-by":"publisher","first-page":"2045853","DOI":"10.1080\/21645515.2022.2045853","volume":"18","author":"K Dhama","year":"2022","unstructured":"Dhama K, Dhawan M, Tiwari R, Emran TB, Mitra S, Rabaan AA, Alhumaid S, Alawi ZA, Al Mutair A. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother. 2022;18(5):2045853.","journal-title":"Hum Vaccin Immunother"},{"key":"3970_CR66","unstructured":"U.S. Food and Drug Administration. FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration. 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-nasal-spray-influenza-vaccine-self-or-caregiver-administration."},{"issue":"3","key":"3970_CR67","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.vaccine.2021.12.002","volume":"40","author":"WL Herring","year":"2022","unstructured":"Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022;40(3):483\u201393.","journal-title":"Vaccine"},{"issue":"7616","key":"3970_CR68","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/bmj.39308.560069.BE","volume":"335","author":"J Appleby","year":"2007","unstructured":"Appleby J, Devlin N, Parkin D. NICE\u2019s cost effectiveness threshold. BMJ. 2007;335(7616):358\u20139.","journal-title":"BMJ"},{"issue":"12","key":"3970_CR69","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/hec.799","volume":"12","author":"D Gyrd-Hansen","year":"2003","unstructured":"Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ. 2003;12(12):1049\u201360.","journal-title":"Health Econ"},{"key":"3970_CR70","unstructured":"Salo H. Economic evaluations in adopting new vaccines in the Finnish national vaccination programme. University of Helsinki; 2017. https:\/\/helda.helsinki.fi\/items\/02eeb8ee-6e38-4aec-b9f7-11c0c113f377."},{"issue":"1","key":"3970_CR71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2021.08.003","volume":"25","author":"M Schurer","year":"2022","unstructured":"Schurer M, Matthijsse SM, Vossen CY, van Keep M, Horscroft J, Chapman AM, Akehurst RL. Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands. Value Health. 2022;25(1):91\u2013103.","journal-title":"Value Health"},{"key":"3970_CR72","unstructured":"Polder J, van Exel J, Kahlman J, Knies S, Mierau J, Vermeulen W, de Wit A, Wouterse B, Rotteveel A: Preventie op waarde schatten: advies technische werkgroep kosten en baten van preventie. In.; 2023."},{"issue":"4","key":"3970_CR73","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hec.3633","volume":"27","author":"L Vallejo-Torres","year":"2018","unstructured":"Vallejo-Torres L, Garcia-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746\u201361.","journal-title":"Health Econ"},{"issue":"6","key":"3970_CR74","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jamainternmed.2024.0212","volume":"184","author":"RC Woodruff","year":"2024","unstructured":"Woodruff RC, Melgar M, Pham H, Sperling LS, Loustalot F, Kirley PD, Austin E, Yousey-Hindes K, Openo KP, Ryan P, et al. Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection. JAMA Intern Med. 2024;184(6):602\u201311.","journal-title":"JAMA Intern Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03970-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-03970-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03970-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:23:52Z","timestamp":1757147032000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-03970-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3970"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-03970-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.06.24311440","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Outside the submitted work, PB declares funding received by his institute from Merck for research on varicella-zoster and Pfizer for research on pneumococcus vaccine, XL declares funding received by her institute from Icosavax, but they have not received any personal fees or other personal benefits. CKJ reports a research grant from Nordsj\u00e6llands Hospital, travel grants from the University of Copenhagen, William Demants Fond in Denmark, and the European Society of Clinical Virology and expert consultation fees from Sanofi, outside of the submitted work. Outside the submitted work, HN declares consulting fees received from WHO, Pfizer, Bill and Medlinda Bill and Melinda Gates Foundation and Sanofi, honoraria for lectures\/presentations from Astra Zeneca, GSK and Pfizer paid to his institution, travel grants from Pfizer and Sanofi, and participation on a Data Safety Monitoring Board or Advisory Board of GSK, Sanofi, Merck, Icosavax, Pfizer (paid to his institution), as well as WHO and ResViNET (unpaid). AUF declares grants\/contracts from Moderna and VAC4EU paid to her institution, outside submitted work. AOS and JDD declares grants\/contracts from Moderna, MSD and GSK paid to their institution, outside submitted work. AOS also declares consultancy fees from GSK and Moderna, outside submitted work. JDD declares consultancy fees and honoraria from GSK, Pfizer and MSD, and travel grants from Sanofi and GSK, outside the submitted work. HS declares attending Adult Immunization Board meetings twice a year, the meetings (and travel) are funded by an unrestricted grant from Vaccines Europe, outside submitted work. LW declares grants received from Research Foundation Flanders (FWO), Antwerp University Research Council and Horizon Europe 2.1 \u2013 Health paid to his institute, outside the submitted work. MJ declares research grants from NIHR, RCUK, BMGF, WHO, Gavi, Wellcome Trust, European Commission, InnoHK, TFGH, CDC, Gates Foundation paid to his institution, outside the submitted work. Other authors declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}